Overview

Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of Camrelizumab with neoadjuvant chemotherapy for resectable thoracic esophageal squamous cell carcinoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Zhejiang Cancer Hospital
Treatments:
Carboplatin
Paclitaxel